Moneycontrol PRO
Open App
you are here: HomeNewsBusiness

IRB Infrastructure completes raising Rs 5,347 crore via preferential issue of shares

As part of the fundraiser, Ferrovial subsidiary Cintra Global SE will invest equity capital of up to Rs 3,180 crore for a 24.9 percent stake in the company, while GIC will invest equity capital of up to Rs 2,167 crore for a 16.9 percent stake.

December 29, 2021 / 04:54 PM IST
Representative image

Representative image

IRB Infrastructure Developers on December 29 completed the equity fundraise to raise Rs 5,347 crore through preferential allotment of shares to a subsidiary of Ferrovial S.A and an affiliate of Singapore’s sovereign wealth fund GIC, the highway construction firm said in a press release.

As part of the fundraiser, Spanish infrastructure company Ferrovial's subsidiary Cintra Global SE will invest equity capital of up to Rs 3,180 crore for a 24.9 percent stake in the company, while GIC will invest equity capital of up to Rs 2,167 crore for a 16.9 percent stake, IRB Infra said.

The issue price for both transactions was set at Rs 211.79 a share.

IRB Infra had announced the fundraiser in October and will use the proceeds from the same to deleverage its balance sheet and have access to new growth capital.

“We are confident that with strong financial and strategic support as well as the guidance of our new investors and stakeholders, IRB will excel across its operations and conquer new peaks of success in India’s highways developments sector," IRB Infra's Chairman & Managing Director Virendra D. Mhaiskar said.

Mhaiskar will continue as the promoter and single-largest shareholder after the completion of the transactions, with an approximate 34 percent stake, and will retain management control of IRB, the company said in a statement.

From the proceeds of the transactions, IRB would use Rs 3,250 crore to repay corporate debt, Rs 1,497 crore as growth capital and Rs 600 crore for general corporate purposes.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Moneycontrol News
ISO 27001 - BSI Assurance Mark